Cargando…

Use of medicines recommended for secondary prevention of acute coronary syndrome

OBJECTIVE: : To analyze if the demographic and socioeconomic variables, as well as percutaneous coronary intervention are associated with the use of medicines for secondary prevention of acute coronary syndrome. METHODS: : In this cohort study, we included 138 patients with acute coronary syndrome,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaedke, Mari Ângela, da Costa, Juvenal Soares Dias, Manenti, Euler Roberto Fernandes, Henn, Ruth Liane, Paniz, Vera Maria Vieira, Nunes, Marcelo Felipe, da Motta, Monique Adriane, Olinto, Maria Teresa Anselmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Saúde Pública da Universidade de São Paulo 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687825/
https://www.ncbi.nlm.nih.gov/pubmed/26759968
http://dx.doi.org/10.1590/S0034-8910.2015049005978
_version_ 1782406672713515008
author Gaedke, Mari Ângela
da Costa, Juvenal Soares Dias
Manenti, Euler Roberto Fernandes
Henn, Ruth Liane
Paniz, Vera Maria Vieira
Nunes, Marcelo Felipe
da Motta, Monique Adriane
Olinto, Maria Teresa Anselmo
author_facet Gaedke, Mari Ângela
da Costa, Juvenal Soares Dias
Manenti, Euler Roberto Fernandes
Henn, Ruth Liane
Paniz, Vera Maria Vieira
Nunes, Marcelo Felipe
da Motta, Monique Adriane
Olinto, Maria Teresa Anselmo
author_sort Gaedke, Mari Ângela
collection PubMed
description OBJECTIVE: : To analyze if the demographic and socioeconomic variables, as well as percutaneous coronary intervention are associated with the use of medicines for secondary prevention of acute coronary syndrome. METHODS: : In this cohort study, we included 138 patients with acute coronary syndrome, aged 30 years or more and of both sexes. The data were collected at the time of hospital discharge, and after six and twelve months. The outcome of the study was the simultaneous use of medicines recommended for secondary prevention of acute coronary syndrome: platelet antiaggregant, beta-blockers, statins and angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker. The independent variables were: sex, age, education in years of attending, monthly income in tertiles and percutaneous coronary intervention. We described the prevalence of use of each group of medicines with their 95% confidence intervals, as well as the simultaneous use of the four medicines, in all analyzed periods. In the crude analysis, we verified the outcome with the independent variables for each period through the Chi-square test. The adjusted analysis was carried out using Poisson Regression. RESULTS: : More than a third of patients (36.2%; 95%CI 28.2;44.3) had the four medicines prescribed at the same time, at the moment of discharge. We did not observe any differences in the prevalence of use in comparison with the two follow-up periods. The most prescribed class of medicines during discharge was platelet antiaggregant (91.3%). In the crude analysis, the demographic and socioeconomic variables were not associated to the outcome in any of the three periods. CONCLUSIONS: : The prevalence of simultaneous use of medicines at discharge and in the follow-ups pointed to the under-utilization of this therapy in clinical practice. Intervention strategies are needed to improve the quality of care given to patients that extend beyond the hospital discharge, a critical point of transition in care.
format Online
Article
Text
id pubmed-4687825
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Faculdade de Saúde Pública da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-46878252015-12-29 Use of medicines recommended for secondary prevention of acute coronary syndrome Gaedke, Mari Ângela da Costa, Juvenal Soares Dias Manenti, Euler Roberto Fernandes Henn, Ruth Liane Paniz, Vera Maria Vieira Nunes, Marcelo Felipe da Motta, Monique Adriane Olinto, Maria Teresa Anselmo Rev Saude Publica Original Articles OBJECTIVE: : To analyze if the demographic and socioeconomic variables, as well as percutaneous coronary intervention are associated with the use of medicines for secondary prevention of acute coronary syndrome. METHODS: : In this cohort study, we included 138 patients with acute coronary syndrome, aged 30 years or more and of both sexes. The data were collected at the time of hospital discharge, and after six and twelve months. The outcome of the study was the simultaneous use of medicines recommended for secondary prevention of acute coronary syndrome: platelet antiaggregant, beta-blockers, statins and angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker. The independent variables were: sex, age, education in years of attending, monthly income in tertiles and percutaneous coronary intervention. We described the prevalence of use of each group of medicines with their 95% confidence intervals, as well as the simultaneous use of the four medicines, in all analyzed periods. In the crude analysis, we verified the outcome with the independent variables for each period through the Chi-square test. The adjusted analysis was carried out using Poisson Regression. RESULTS: : More than a third of patients (36.2%; 95%CI 28.2;44.3) had the four medicines prescribed at the same time, at the moment of discharge. We did not observe any differences in the prevalence of use in comparison with the two follow-up periods. The most prescribed class of medicines during discharge was platelet antiaggregant (91.3%). In the crude analysis, the demographic and socioeconomic variables were not associated to the outcome in any of the three periods. CONCLUSIONS: : The prevalence of simultaneous use of medicines at discharge and in the follow-ups pointed to the under-utilization of this therapy in clinical practice. Intervention strategies are needed to improve the quality of care given to patients that extend beyond the hospital discharge, a critical point of transition in care. Faculdade de Saúde Pública da Universidade de São Paulo 2015-12-16 /pmc/articles/PMC4687825/ /pubmed/26759968 http://dx.doi.org/10.1590/S0034-8910.2015049005978 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Gaedke, Mari Ângela
da Costa, Juvenal Soares Dias
Manenti, Euler Roberto Fernandes
Henn, Ruth Liane
Paniz, Vera Maria Vieira
Nunes, Marcelo Felipe
da Motta, Monique Adriane
Olinto, Maria Teresa Anselmo
Use of medicines recommended for secondary prevention of acute coronary syndrome
title Use of medicines recommended for secondary prevention of acute coronary syndrome
title_full Use of medicines recommended for secondary prevention of acute coronary syndrome
title_fullStr Use of medicines recommended for secondary prevention of acute coronary syndrome
title_full_unstemmed Use of medicines recommended for secondary prevention of acute coronary syndrome
title_short Use of medicines recommended for secondary prevention of acute coronary syndrome
title_sort use of medicines recommended for secondary prevention of acute coronary syndrome
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687825/
https://www.ncbi.nlm.nih.gov/pubmed/26759968
http://dx.doi.org/10.1590/S0034-8910.2015049005978
work_keys_str_mv AT gaedkemariangela useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT dacostajuvenalsoaresdias useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT manentieulerrobertofernandes useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT hennruthliane useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT panizveramariavieira useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT nunesmarcelofelipe useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT damottamoniqueadriane useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome
AT olintomariateresaanselmo useofmedicinesrecommendedforsecondarypreventionofacutecoronarysyndrome